New therapy that could help against one of the hardest-to-treat cancers

A new therapeutic approach has emerged as a potential breakthrough in the fight against one of the most aggressive and difficult-to-treat forms of brain cancer—glioblastoma. A recent study published in the scientific journal *Oncoscience* reports promising results regarding a novel treatment involving a modified form of vitamin B12 known as nitrosylcobalamin (NO-Cbl). This compound was tested for its ability to cross the blood-brain barrier and target tumors directly, offering a potentially more effective way to treat this deadly disease.

Glioblastoma is among the most lethal types of brain cancer, with patients typically surviving less than 15 months on average after diagnosis, even following surgery, radiation therapy, and chemotherapy. One of the major challenges in treating this condition is the presence of the blood-brain barrier, which prevents many drugs from reaching the tumor site. Researchers sought to determine whether NO-Cbl could overcome this obstacle and deliver its active components directly to the tumor while minimizing damage to healthy tissues.

The research team conducted experiments using both cancerous cell lines and mice models affected by glioblastoma. The findings indicated that NO-Cbl successfully crossed the blood-brain barrier and accumulated primarily in the tumor tissue rather than in healthy areas. It remained active within the tumor for at least 24 hours after administration and demonstrated activity against several types of cancer. According to the researchers, these results suggest that the therapy can deliver the active substance directly to the tumor, reducing harm to surrounding healthy cells.

In laboratory tests, combining NO-Cbl with temozolomide—a standard drug used in glioblastoma treatment—or with the experimental therapy TRAIL significantly inhibited the growth of cancerous cells more effectively than either treatment alone. The authors noted that this pilot study shows that NO-Cbl crosses the blood-brain barrier, selectively accumulates in the brain's tumor tissue, and works synergistically with existing and experimental therapies for glioblastoma.

Researchers believe this therapy might also help overcome the resistance that glioblastoma develops against current treatments. They explain that NO-Cbl activates mechanisms that promote the death of cancerous cells and disrupt signals that allow them to survive, making tumors more responsive to treatment. However, they emphasize that this is an early-stage study and that the therapy is not yet ready for use in patients.

The researchers have planned further studies to confirm their findings, determine the optimal dosage, and better understand how this therapy functions. Despite these remaining steps, the preliminary results suggest that this modified form of vitamin B12 could represent a new and promising approach in the treatment of glioblastoma, improving the delivery of drugs to the brain and enhancing the effectiveness of existing therapies.

This discovery comes amid growing efforts to find innovative solutions for cancers that remain resistant to conventional treatments. Glioblastoma, in particular, has long posed significant challenges due to its location and the limitations imposed by the blood-brain barrier. The success of NO-Cbl in crossing this barrier marks a critical step forward in developing targeted therapies that can reach the tumor without affecting other parts of the body.

Scientists involved in the study expressed cautious optimism about the potential impact of this new approach. While much work remains before clinical trials can begin, the initial data provide hope for future advancements in glioblastoma treatment. Researchers are now focused on refining the method, ensuring safety, and exploring ways to integrate this therapy into existing treatment protocols.

As the field continues to evolve, the possibility of using modified vitamins or similar compounds to combat aggressive cancers opens up new avenues for research and treatment. The study highlights the importance of interdisciplinary collaboration between chemists, biologists, and medical professionals in addressing some of the most complex health challenges. With continued investment and research, such innovations could pave the way for more effective and personalized cancer care in the years ahead.